ArticleClinical Medicine Insights. Oncology2025
Impact of Latent Tuberculosis Infection and T-SPOT.TB Dynamics Alterations on Prognosis in Advanced NSCLC Treated With ICIs--IPTW-Based Retrospective Study.
Article in Clinical Medicine Insights. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Conversion to LCP Tacrolimus Mitigates Calcineurin-Induced Nephrotoxicity in Patients After Liver Transplantation.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the impact of latent tuberculosis infection (LTBI) on the prognosis of non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 immunotherapy and to assess the correlation between dynamic alterations in T-SPOT.TB results and prognosis. Methods: This retrospective cohort study analyzed clinical data from 127 patients with NSCLC who received anti-PD-1 therapy and underwent T-SPOT.TB testing at our institution between January 2020 and March 2024. Baseline imbalances between groups were addressed using inverse probability of treatment weighting (IPTW). Restricted cubic spline (RCS) modeling, Cox regression and other analyses were conducted both before and after IPTW. Results: Among the entire cohort, 50 patients were in the LTBI group and 77 in the Normal group. No significant differences were observed in mPFS or mOS between the two groups. RCS analysis revealed a nonlinear (U-shaped) relationship between pre-TSPOT values and OS. Patients with a T-SPOT positive (but value ⩽18) exhibited longer OS compared with the other two groups (HR = 0.13, 95% CI [0.03 ~ 0.54], Conclusions: Although no statistically significant differences in treatment efficacy and prognosis were observed between the LTBI and Normal groups, this finding should not be interpreted as therapeutic equivalence, particularly given the limited sample size. Pre-treatment T-SPOT values showed a nonlinear (U-shaped) relationship with patient prognosis (OS). Lower pre-treatment T-SPOT value were associated with longer OS. The dynamic changes in T-SPOT during treatment were not significantly associated with outcomes. Four patients developed active tuberculosis during immunotherapy, with heterogeneous T-SPOT patterns, underscoring the need for TB monitoring in ICI-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.